A quality agreement — sometimes called a Quality Technical Agreement (QTA) or Supply Quality Agreement — is a formal document that defines the quality responsibilities and expectations between a pharmaceutical company (or research organization) and its peptide raw material manufacturers. While standard purchase orders address commercial terms, quality agreements address the quality system requirements that govern the relationship. For any pharmaceutical-grade peptide raw material supply, a quality agreement is not optional.
Why Quality Agreements Are Necessary
Without a quality agreement, there is no formal documentation of:
- What specifications the peptide raw material must meet
- Who is responsible for which quality activities (testing, review, release)
- What happens when deviations occur
- How manufacturing changes will be communicated
- What audit rights the buyer retains
Regulatory expectations (ICH Q10, FDA process validation guidance) and good industry practice both indicate that quality agreements should be in place with critical material suppliers. Auditors and regulatory reviewers will ask for them.
Core Sections of a Quality Agreement with Peptide Raw Material Manufacturers
Scope and Purpose
Identifies the specific peptide raw materials covered, the manufacturing site, and the parties to the agreement.
Product Specifications
Documents the agreed specifications for each covered peptide raw material — including purity limits, identity tests, and any additional parameters. Specifications in the quality agreement should match those in the purchase order and the manufacturer’s internal specification.
Responsibilities Matrix
A clear responsibilities matrix defining who performs, who reviews, and who approves each quality activity:
- Synthesis process validation
- Raw material testing and release
- In-process testing
- Final release testing
- CoA generation and approval
- Stability testing
- Environmental monitoring
- Calibration and equipment qualification
Change Control
Defines what manufacturing changes require notification, and what timeline is required:
- Notification changes: minor changes the manufacturer must inform the buyer of, but that do not require pre-approval (e.g., reagent supplier changes for non-critical materials)
- Pre-approval changes: significant changes requiring buyer review and approval before implementation (e.g., synthesis process changes, purification method changes, facility modifications)
For GMP peptide raw materials, changes with potential regulatory impact may also require regulatory authority notification.
Non-Conformance and Deviation Management
- How out-of-specification (OOS) results are handled
- Investigation requirements and timelines for deviations
- Disposition process for non-conforming batches
- Right of buyer to be informed of deviations affecting shipped material
Audit Rights
Specifies the buyer’s right to audit the manufacturer’s facilities and quality systems — including frequency, notice period, and scope. Most quality agreements include the right to conduct audits at least annually (or more frequently for cause) with reasonable notice.
Document Retention
Specifies how long the manufacturer must retain batch records, analytical data, and quality documentation — typically minimum of five years or the lifetime of any product incorporating the material, whichever is longer.
Practical Considerations
Quality agreements should be reviewed and updated whenever significant changes occur to the product, process, or quality system — and should be formally reviewed at least every two to three years even without specific changes.
New quality agreements should be negotiated before manufacturing begins, not after problems arise. Many peptide raw material manufacturers have standard quality agreement templates that can serve as a starting point.
FAQ
Q: Are quality agreements required for research-grade peptide raw materials?
They are not a regulatory requirement for research-grade materials, but they are good practice for any ongoing supplier relationship where product quality expectations need to be formally documented. A simplified quality agreement covering key specifications and non-conformance procedures is appropriate even for research applications.
Q: What if a manufacturer refuses to sign a quality agreement?
For pharmaceutical-grade supply, a manufacturer that refuses to sign a reasonable quality agreement is effectively not qualified as a pharmaceutical supplier. This should be treated as a disqualifying finding.
Conclusion
Quality agreements formalize the shared quality responsibilities between buyers and peptide raw material manufacturers. For pharmaceutical programs, they are essential regulatory infrastructure; for research programs, they represent good supply chain management practice. Investing the time to negotiate comprehensive quality agreements with key peptide raw material manufacturers establishes the accountability framework that supports consistent, reliable supply throughout program development.
Product Disclaimer & Terms of Use
IMPORTANT NOTICE: FOR RESEARCH USE ONLY (RUO)
This product is intended exclusively for laboratory research and scientific development purposes. It is NOT a drug, food, medical device, cosmetic, or diagnostic product.